论文部分内容阅读
目的观察和评价分析沙利度胺联合化疗治疗急性髓系白血病的临床治疗效果及安全性。方法选择2014年6月至2016年5月期间收治的48例初发急性髓系白血病患者作为研究对象,随机分为治疗组和对照组,每组24例。对照组患者给予常规化疗,治疗组患者在接受常规化疗基础上给予沙利度胺。观察并对比两组患者的临床治疗效果和不良反应。结果治疗组患者的临床治疗缓解率明显高于对照组,组间对比差异有统计学意义(P<0.05);两组患者治疗相关不良反应比较差异无统计学意义。结论沙利度胺联合常规化疗治疗急性髓系白血病可提高临床缓解率,耐受性可,值得临床推广使用。
Objective To observe and evaluate the clinical efficacy and safety of thalidomide combined with chemotherapy in the treatment of acute myeloid leukemia. Methods Forty-eight patients with acute myeloid leukemia admitted from June 2014 to May 2016 were selected as study subjects and randomly divided into treatment group and control group with 24 cases in each group. Patients in the control group were given conventional chemotherapy, and patients in the treatment group were given thalidomide on the basis of conventional chemotherapy. The clinical effects and adverse reactions of the two groups were observed and compared. Results The response rate of treatment in the treatment group was significantly higher than that in the control group, with significant difference between the two groups (P <0.05). There was no significant difference in the treatment-related adverse reactions between the two groups. Conclusion Thalidomide combined with conventional chemotherapy in the treatment of acute myeloid leukemia can improve the clinical remission rate, tolerability may be worthy of clinical promotion and use.